Board Member
Eledon Pharmaceuticals, Inc. (ELDN)Equibles does not estimate personal net worth.
Get an email with a short summary when Eledon Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ELDN alertsDavid-Alexandre Gros is recorded as Board Member and CEO at Eledon Pharmaceuticals, Inc. (ELDN). The newest filing on record that lists David-Alexandre Gros as Board Member and CEO at Eledon Pharmaceuticals, Inc. (ELDN) is dated April 30, 2026. The proxy statement of Eledon Pharmaceuticals, Inc. reports total compensation of $3,216,148 for David-Alexandre Gros in fiscal 2025, including a base salary of $613,196. Disclosed compensation is on record for 6 fiscal years. David-Alexandre Gros has spoken on 9 earnings calls across 1 company, most recently for Eledon Pharmaceuticals, Inc. on May 11, 2023. Eledon Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Eledon Pharmaceuticals, Inc. includes David-Alexandre "DA" C. Gros, M.D. (CEO and Board Member), David-Alexandre C. Gros (CEO and Board Member), David-Alexandre C. Gros, M.D. (CEO and Board Member) and 7 others.
“We began the year by announcing our primary organizational focus on our kidney transplantation program, and have since directed our resources and efforts to advance this program forward.”
“We made the strategic decision as we entered 2023 to primarily focus our financial and organizational resources on our kidney transplantation program to continue to seek non-dilutive financing for the ALS program and to deprioritize our IgA nephropathy and islet cell transplant programs.”
“Following the positive Phase 2a ALS results in the second quarter, we continue to make important progress in our three ongoing clinical trials evaluating tegoprubart in kidney transplantation, IgA Nephropathy or IgAN, and islet cell transplantation.”
“The second quarter marked the beginning of an exciting period for Eledon as we reported the first of four distinct clinical readouts from our tegoprubart pipeline with positive phase 2a results in ALS.”
“We made important progress during the first quarter of 2022 and look forward to continuing this momentum through the remainder of the year.”
Start not stated–present
Last confirmed April 30, 2026
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $613,196 | $3,216,148 |
| 2024 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $582,269 | $5,644,970 |
| 2023 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $559,478 | $2,553,153 |
| 2022 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $532,503 | $1,118,493 |
| 2021 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $503,654 | $747,504 |
| 2020 | Eledon Pharmaceuticals, Inc. (ELDN) | Chief Executive Officer | $150,000 | $7,419,307 |
